ShyamasundaranKottililMDPhD, MACP, FRCP, FIDSA, FAASLD

Clinical Trials

• Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV Start of enrollment: 1993 Mar 09

  Recruiting

• Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection Start of enrollment: 2010 Jul 01

  Terminated

• Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection Start of enrollment: 2011 Aug 23

  Completed

• Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV Start of enrollment: 2011 Sep 01

  Terminated

  Phase 4

• Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Start of enrollment: 2019 Dec 01

  Withdrawn

  Phase 4

• Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003) Start of enrollment: 2020 Aug 31

  Terminated

  Phase 2

• Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) Start of enrollment: 2020 Apr 24

  Completed

  Phase 3

• Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects Start of enrollment: 2023 Sep 27

  Completed

  Phase 1

  Roles: Contact

• Join now to see all